Skip to content

We Took A Deep Dive into Cannabis, Marijuana, and CBD — Here’s What We Found

This image depicts a cannabis plant.

LegitScript’s Associate General Counsel, Gerard Olson, takes a deep dive into the regulatory landscape of cannabis, marijuana, and CBD. Read more to understand the regulatory landscape of these products, recent stances the FDA has taken, and what problematic products we’re finding online. Or, watch the full webinar by clicking the button below.

Let’s Define the Difference Between Cannabis, Marijuana, Hemp, and CBD

You’ve heard many terms to describe it — cannabis, marihuana, marijuana and many more. So what’s the difference between the descriptors?

Cannabis is short for Cannabis sativa, Cannabis indica, and Cannabis ruderalis — all three are included in this plant family. Cannabis produces more than 540 chemical substances, and the term is often used to describe all products derived from the plant.

Marijuana is a type of cannabis, and the Drug Enforcement Administration describes it as a mind-altering drug in which the flowers, stems, seeds, and leaves are smoked, vaped, or otherwise ingested for their psychoactive effect. It contains delta-9 tetrahydrocannabinol (THC) — the most well-known chemical derived from cannabis that causes the psychoactive high many associate with the drug.

CBD is one of many cannabinoids found in the cannabis plant that, unlike THC variants, is not generally considered psychoactive. So far, it has been approved for use in an anti-seizure medication but lacks approval for use in supplements and food products.

Lastly, hemp is the fiber or edible seeds from the Cannabis sativa plant that contains low concentrations of THC. It’s safe to manufacture a multitude of products from hemp that compete with more common markets like cotton.

Now that we understand the difference between each, let's dive into the FDA’s stance on cannabis.

 

The FDA’s Stance on Cannabis Products Post-Legalization

In 1996 California became the first state to legalize medicinal marijuana use — and in the years to come most of the country did the same. Currently, there are only four states in the US where marijuana is still illegal.

For CBD, the 2018 Farm Bill opened the door for use in topicals and cosmetics but not food or supplements.

In January of this year, the FDA concluded that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol. The FDA tasked Congress with discovering “a new way forward.”

In the meantime, the administration has sent a slew of warning letters for products containing CBD that make problematic drug claims and also call out CBD as an unsafe food additive.

 

LegitScript Uncovers Problematic Products Like These

Because cannabis produces so many substances, it’s no surprise some of them lacking explicit regulation are making their way onto the market. The most common of the problematic products sold online is delta-8 THC.

Delta-8 THC is derived from hemp or cannabis. Its chemical compound is similar to delta-9 THC in structure and it’s also psychoactive (though considered less potent). The FDA took a clear stance on delta-8 THC, stating it’s not safe to consume.

🚩 Look out for merchants selling delta-8 THC who claim it is legal to sell everywhere. Many US states have now explicitly banned delta-8 THC.

 

LegitScript regularly identifies products sold online containing potentially problematic cannabinoids such as these:

  • Delta-8 THC
  • Delta-10 THC
  • THC-O-acetate
  • 9-Nor-9β-hydroxyhexahydrocannabinol (HHC)
  • Cannabigerol (CBG)
  • Cannabinol (CBN)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • HU-331
  • Cannabidiol-Hydroxy Quinone (CBD HQ)

 

Take A Deep Dive Into Our Webinar Series

Are you curious for more information on the various chemicals cannabis produces, and the products LegitScript uncovers? Click the button below to learn:

  • The history of cannabis products
  • The various chemicals derived from cannabis and hemp
  • The full regulatory landscape of cannabis, marijuana, and CBD

 

Smelting words into a specialty since 2020, Thea Le Fevre specializes in B2B SaaS Content Marketing. Take a deep dive into her work for up-to-date industry news surrounding issues in payments risk & compliance, trust & safety, regulatory compliance, and more.

Recent Blog Articles

Why the Next 6 Months Will Redefine Merchant Risk Management

Two deadlines. One turning point. On October 1, 2025, enforcement begins on the Visa Acquirer Monitoring Program (VAMP). Just three months later, on January 1, 2026, Mastercard's Merchant Monitoring Program (MMP) revised standards take effect. Together, these updates mark one of the most significant...

Maverick Payments and LegitScript Weigh in on AI’s Growing Role in Payments

Artificial intelligence (AI) may be one of the hottest topics in payment processing, but industry leaders say its role in payments is an opportunity that requires a thoughtful approach and critical thinking. That was the central theme of LegitScript's recent webinar, "Maverick Payments on What AI Re...

This Is Why Renewing Your LegitScript Certification Is So Important

You already know that LegitScript's industry-leading certification services represent a seal of approval recognized by both the public and business partners such as advertising platforms and payment processors. Keep reading to understand why renewing your certification is essential to maintaining co...

​​What the EU’s Crackdown on Dangerous Products Online Means for You

Faulty baby pacifiers. Toxic children's raincoats. Cosmetics with banned chemicals. These are just some of the products recently purchased through an EU-wide mystery shopper operation on major e-commerce platforms Temu and Shein.  The findings may have widespread implications for e-commerce platform...